Advanced stage
neuroblastoma has a poor clinical outcome and microtubule-destabilizing agents, such as the
Vinca alkaloids, are an important component in the treatment of this childhood
cancer.
Vinca alkaloids bind to
beta-tubulin on the alpha/
beta-tubulin heterodimer and disrupt microtubule dynamics, leading to cell death. To date, studies examining the contribution of microtubules and associated
proteins to the efficacy of microtubule-destabilizing agents in
neuroblastoma have been limited. In this study, BE2-C
neuroblastoma cells previously selected for resistance to either
vincristine (BE/VCR10) or
colchicine (BE/CHCb0.2) were found to display significant decreases in neuronal-specific class III
beta-tubulin. Interestingly,
vincristine-selected cells exhibited increased levels of polymerized
tubulin that were not due to
alpha-tubulin and class I, II, or III
beta-tubulin mutations. Expression levels of the microtubule-depolymerizing
protein stathmin were significantly increased in BE/VCR10 cells. In contrast, levels of MAP2a and MAP2b were relatively unaltered. A marked decrease in the neuronal
protein, MAP2c, was identified in the
vincristine-selected cells and, to a lesser extent, in the
colchicine-selected cells. This is the first report describing specific microtubule alterations in
neuroblastoma cells resistant to
tubulin-targeted agents. The results indicate a need to identify the factors responsible for resistance to
tubulin-targeted agents in
neuroblastoma so that improved and novel treatment strategies can be developed for this
drug refractory disease.